LIVER STEM CELLS AND HUMANIZED MICE: A NEW MODEL FOR HCV

肝干细胞和人源化小鼠：HCV 的新模型

• 批准号: 6256355
• 负责人: ERIC LAGASSE
• 金额: $ 30万
• 依托单位: STEMCELLS, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-02-15 至 2003-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6256355
• 关键词: NOD mouse; SCID mouse; cell transplantation; disease /disorder model; hepatitis C; hepatitis C virus; hepatocyte growth factor; laboratory mouse; liver cells; model design /development; stem cells

DESCRIPTION: This application proposes to use NOD/SCID mice transplanted (intrasplenically or under kidney capsule) with human hepatocytes for HCV infection. The project will first identify hepatocyte subpopulations that are most susceptible to HCV infection, and examine the possible effects of hepatocyte growth factor (HGF) on hepatocyte growth in the transplanted mice. The same approach will also be applied to fumarylacetoacetate hydrolase (FAH) mice to enrich transplanted human hepatocytes. For all of the optimization procedures, hepatitis delta virus (HDV) will be used as a surrogate virus for HCV. Eventually, these humanized mice will be tested for HCV infections. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：本申请建议使用移植的 NOD/SCID 小鼠 （脾内或肾包膜下）与人肝细胞治疗 HCV 感染。该项目将首先确定肝细胞亚群 最容易感染 HCV，并检查可能的影响 肝细胞生长因子（HGF）对移植小鼠肝细胞生长的影响。 同样的方法也将应用于富马酰乙酰乙酸水解酶（FAH） 小鼠富集移植的人肝细胞。对于所有的优化 程序中，丁型肝炎病毒（HDV）将被用作替代病毒 丙肝病毒。最终，这些人源化小鼠将接受丙肝病毒感染测试。 拟议的商业应用：不可用